Literature DB >> 31088885

Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.

Christina Korownyk1, Danielle Perry2, Joey Ton3, Michael R Kolber4, Scott Garrison5, Betsy Thomas6, G Michael Allan7, Nicolas Dugré8, Caitlin R Finley9, Rhonda Ting10, Peter Ran Yang9, Ben Vandermeer11, Adrienne J Lindblad12.   

Abstract

OBJECTIVE: To summarize the best available evidence regarding various topics related to primary care management of opioid use disorder (OUD). DATA SOURCES: MEDLINE, Cochrane Library, Google, and the references of included studies and relevant guidelines. STUDY SELECTION: Published systematic reviews and newer randomized controlled trials from the past 5 to 10 years that investigated patient-oriented outcomes related to managing OUD in primary care, diagnosis, pharmacotherapies (including buprenorphine, methadone, and naltrexone), tapering strategies, psychosocial interventions, prescribing practices, and management of comorbidities. SYNTHESIS: From 8626 articles, 39 systematic reviews and an additional 26 randomized controlled trials were included. New meta-analyses were performed where possible. One cohort study suggests 1 case-finding tool might be reasonable to assist with diagnosis (positive likelihood ratio of 10.3). Meta-analysis demonstrated that retention in treatment improves when buprenorphine or methadone are used (64% to 73% vs 22% to 39% for control), when OUD is treated in primary care (86% vs 67% in specialty care, risk ratio [RR] of 1.25, 95% CI 1.07 to 1.47), and when counseling is added to pharmacotherapy (74% vs 62% for controls, RR = 1.20, 95% CI 1.06 to 1.36). Retention was also improved with naltrexone (33% vs 25% for controls, RR = 1.35, 95% CI 1.11 to 1.64) and reduced with medication-related contingency management (eg, loss of take-home doses as a punitive measure; 68% vs 77% for no contingency, RR = 0.86, 95% CI 0.76 to 0.99).
CONCLUSION: There is reasonable evidence that patients with OUD should be managed in the primary care setting. Diagnostic criteria for OUD remain elusive, with 1 reasonable case-finding tool. Methadone and buprenorphine improve treatment retention, while medication-related contingency methods could worsen retention. Counseling is beneficial when added to pharmacotherapy. Copyright© the College of Family Physicians of Canada.

Entities:  

Year:  2019        PMID: 31088885      PMCID: PMC6516704     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

Review 2.  Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

3.  A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Authors:  Anne M Neumann; Richard D Blondell; Urmo Jaanimägi; Amanda K Giambrone; Gregory G Homish; Jacqueline R Lozano; Urszula Kowalik; Mohammadreza Azadfard
Journal:  J Addict Dis       Date:  2013

4.  Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Authors:  Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling
Journal:  J Stud Alcohol Drugs       Date:  2013-07       Impact factor: 2.582

Review 5.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 6.  A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014.

Authors:  Danielle R Davis; Allison N Kurti; Joan M Skelly; Ryan Redner; Thomas J White; Stephen T Higgins
Journal:  Prev Med       Date:  2016-08-08       Impact factor: 4.018

Review 7.  Opioid agonist treatment for pharmaceutical opioid dependent people.

Authors:  Suzanne Nielsen; Briony Larance; Louisa Degenhardt; Linda Gowing; Chyanne Kehler; Nicholas Lintzeris
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

8.  Methodology in conducting a systematic review of systematic reviews of healthcare interventions.

Authors:  Valerie Smith; Declan Devane; Cecily M Begley; Mike Clarke
Journal:  BMC Med Res Methodol       Date:  2011-02-03       Impact factor: 4.615

Review 9.  Primary care models for treating opioid use disorders: What actually works? A systematic review.

Authors:  Pooja Lagisetty; Katarzyna Klasa; Christopher Bush; Michele Heisler; Vineet Chopra; Amy Bohnert
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more
  5 in total

1.  Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.

Authors:  Susan L Calcaterra; Richard Bottner; Marlene Martin; Honora Englander; Zoe M Weinstein; Melissa B Weimer; Eugene Lambert; Matthew V Ronan; Sergio Huerta; Tauheed Zaman; Monish Ullal; Alyssa F Peterkin; Kristine Torres-Lockhart; Megan Buresh; Meghan T O'Brien; Hannah Snyder; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

2.  Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses.

Authors:  Danielle Rice; Kimberly Corace; Dianna Wolfe; Leila Esmaeilisaraji; Alan Michaud; Alicia Grima; Bradley Austin; Reuben Douma; Pauline Barbeau; Claire Butler; Melanie Willows; Patricia A Poulin; Beth A Sproule; Amy Porath; Gary Garber; Sheena Taha; Gord Garner; Becky Skidmore; David Moher; Kednapa Thavorn; Brian Hutton
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

3.  "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Addict Sci Clin Pract       Date:  2021-01-27

Review 4.  The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis.

Authors:  Daniel J Devoe; Gina Dimitropoulos; Alida Anderson; Anees Bahji; Jordyn Flanagan; Andrea Soumbasis; Scott B Patten; Tom Lange; Georgios Paslakis
Journal:  J Eat Disord       Date:  2021-12-11

5.  Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.

Authors:  Natrina L Johnson; Sugy Choi; Carolina-Nicole Herrera
Journal:  J Subst Abuse Treat       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.